Hero Image

Osteoporosis Drugs: Side Effects and Safety Tips

Osteoporosis medicines can be life-changing for people at risk of fractures.

Yet like all therapies, they come with potential side effects that are worth understanding so you can make informed, confident decisions with your healthcare provider.

What osteoporosis drugs do and why they’re prescribed

Most osteoporosis drugs fall into two broad groups: antiresorptives, which slow the breakdown of bone, and anabolics, which stimulate new bone formation. Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) and denosumab are common antiresorptives; selective estrogen receptor modulators (SERMs) such as raloxifene and menopausal estrogen therapy also reduce bone resorption in select patients. Anabolics include teriparatide and abaloparatide (PTH/PTHrP analogs) and romosozumab (a sclerostin inhibitor that has both anabolic and antiresorptive effects).

When taken correctly, these medications substantially reduce fractures—typical relative risk reductions are about 30–70% for vertebral fractures and 20–50% for hip and other nonvertebral fractures, depending on the drug and patient risk profile. Benefits usually begin within months and grow over the first 1–2 years, especially for patients with prior fractures or very low bone mineral density (BMD).

Choice of therapy depends on your fracture risk, other medical conditions, and preferences. For many at moderate risk, an oral bisphosphonate is first-line; for very high risk or multiple recent fractures, an anabolic such as teriparatide/abaloparatide or a romosozumab-then-antiresorptive sequence may be considered. Because bisphosphonates persist in bone, some patients can take a “drug holiday” after 3–5 years if risk becomes lower; others may continue or switch based on BMD trends and fracture history.

Common short‑term side effects and how to prevent them

Oral bisphosphonates (alendronate, risedronate, ibandronate): The most frequent issues are gastrointestinal. Some people develop heartburn, nausea, esophageal irritation, or abdominal pain, particularly if dosing instructions aren’t followed. To minimize problems:

  • Take first thing in the morning on an empty stomach with a full glass (8 oz/240 mL) of plain water.
  • Do not lie down, eat, or drink anything besides water for at least 30 minutes (60 minutes for ibandronate).
  • Avoid taking other medicines, coffee/tea, calcium, or vitamins for that window.
  • Tell your clinician if you have swallowing difficulties, Barrett’s esophagus, or active ulcers—an alternative (weekly, monthly, or non‑oral) may be safer.

Intravenous bisphosphonates (zoledronic acid): Up to a third of first‑time recipients experience a short “flu‑like” reaction—fever, muscle aches, fatigue—within 1–3 days. It usually resolves within 48–72 hours; hydration and acetaminophen/ibuprofen can help. This reaction tends to be milder or absent with future infusions.

Denosumab: Possible effects include mild injection‑site reactions, skin rashes/eczema, and low calcium in those with vitamin D deficiency or kidney disease. Ensuring adequate calcium and vitamin D before the first dose lowers risk.

Anabolic agents (teriparatide, abaloparatide): Transient nausea, dizziness, leg cramps, or mild increases in calcium can occur, usually early in treatment. Rotating injection sites helps reduce skin irritation.

Calcitonin nasal spray: Now rarely used for osteoporosis because of limited fracture benefit and a past malignancy signal; nasal irritation and headaches are common.

Long‑term risks you should know

Atypical femoral fractures (AFF) with long‑term antiresorptives

After many years on bisphosphonates (and much less commonly with denosumab), a rare stress fracture can occur in the thigh bone, often preceded by weeks of dull, aching pain in the thigh or groin. Estimated rates with prolonged use range from roughly 3 to 50 per 100,000 patient‑years, with higher risk after 5–8 years of continuous therapy. Strategies to reduce risk include periodic reassessment of need, considering a drug holiday for appropriate patients, and prompt evaluation of persistent thigh pain (X‑rays or MRI if initial films are negative).

Osteonecrosis of the jaw (ONJ)

ONJ—nonhealing exposure of the jawbone—is very uncommon at osteoporosis doses (about 1 in 10,000 to 1 in 100,000 patient‑years) but more common with high oncology doses. Risk rises after invasive dental procedures, poor oral hygiene, glucocorticoid use, or smoking. Practical steps: maintain regular dental care, treat active dental disease before starting therapy when possible, and inform your dentist about your medication. Most dental work can be done safely with careful planning.

Rebound vertebral fractures after stopping denosumab

Denosumab’s effects wear off quickly if doses are delayed or stopped; this can lead to rapid bone loss and multiple vertebral fractures. To avoid this, never miss scheduled injections (every 6 months) and, if stopping, transition to a bisphosphonate on time per your prescriber’s plan.

Duration limits and safety for anabolic therapies

Teriparatide and abaloparatide have a recommended lifetime limit of 2 years because of osteosarcoma findings in rodent studies; real‑world human risk appears extremely low, but the limit remains. After completing an anabolic course, switching to an antiresorptive helps preserve gains.

Romosozumab and cardiovascular signal

Some trials observed more serious cardiovascular events (heart attack, stroke) with romosozumab versus comparators, prompting a boxed warning in several countries. It’s generally avoided in patients with a heart attack or stroke in the previous year; clinicians weigh benefits and risks carefully in others.

Cardiovascular considerations across therapies

SERMs (raloxifene): Increase the risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism). The absolute risk is small for most patients but meaningful—on the order of a few additional events per 1,000 women per year. Avoid in people with a history of clots or high clotting risk. Raloxifene may also slightly raise stroke risk in certain high‑risk populations.

Menopausal estrogen therapy: Can reduce fractures but is used primarily for bothersome menopausal symptoms; it can increase risks of clots and stroke and, depending on regimen and duration, breast cancer. It’s typically reserved for younger postmenopausal women with symptoms and lower cardiovascular risk.

Bisphosphonates: No strong evidence of increased heart attack or stroke, though research is ongoing; overall cardiovascular effects appear neutral.

Practical tip: If you have prior clots, recent heart attack or stroke, uncontrolled hypertension, or smoke, discuss SERM/estrogen alternatives and whether romosozumab is appropriate.

Organ‑specific considerations and monitoring

Kidneys: IV bisphosphonates (especially zoledronic acid) are not recommended in significant chronic kidney disease (e.g., estimated GFR below ~35 mL/min). Oral agents require caution if kidney function is reduced. Denosumab is not cleared by the kidneys but can cause low calcium in advanced CKD—optimize calcium/vitamin D and monitor closely.

Calcium and vitamin D: Inadequate intake increases the risk of hypocalcemia with antiresorptives and limits the benefit of all osteoporosis drugs. Most adults with osteoporosis aim for about 1,200 mg/day of total calcium (diet plus supplements) and 800–1,000 IU/day of vitamin D, adjusted to keep 25‑OH vitamin D in the sufficient range per your clinician.

Gastrointestinal disease: People with active esophagitis, strictures, or significant reflux may not tolerate oral bisphosphonates; IV or subcutaneous options avoid the esophagus.

Dental health: Complete necessary invasive dental work before starting long‑term antiresorptives when possible, and keep routine dental visits to lower ONJ risk.

An actionable monitoring and safety checklist

  • Before starting: Review fracture risk, other medications (especially steroids, PPIs, aromatase inhibitors), kidney function, calcium/vitamin D status, dental issues, and personal cardiovascular/clot history.
  • How to take: If oral bisphosphonate, learn exact dosing steps and set reminders. If denosumab, schedule injections every 6 months and plan the follow‑on therapy before the first dose.
  • Lab checks: Vitamin D and calcium at baseline; creatinine for IV bisphosphonates; repeat labs after starting denosumab or anabolics if you’re at risk for low or high calcium.
  • BMD tracking: Repeat DXA every 1–2 years to gauge response; sooner if there’s a new fracture.
  • Lifestyle foundation: Weight‑bearing and resistance exercise, fall‑prevention measures at home, smoking cessation, and limiting alcohol all improve outcomes and complement medication benefits.

When to call your clinician promptly

  • New or worsening thigh or groin pain while on long‑term antiresorptives (possible atypical femur fracture).
  • Jaw pain, swelling, or exposed bone in the mouth, especially after dental work (possible ONJ).
  • Signs of a blood clot: unilateral leg swelling, warmth, chest pain, or sudden shortness of breath (especially on SERMs/estrogen).
  • Symptoms of low calcium after denosumab or IV bisphosphonate: numbness/tingling around the mouth or in fingers, muscle cramps, or spasms.
  • Severe or persistent gastrointestinal pain or difficulty swallowing on oral bisphosphonates.

Bottom line

Osteoporosis drugs markedly reduce fracture risk and can preserve independence and quality of life. Knowing the potential side effects—gastrointestinal symptoms, rare long‑term complications like atypical femoral fracture or osteonecrosis of the jaw, and specific cardiovascular considerations—helps you and your clinician tailor therapy to your health profile. With the right choice of medication, proper dosing, adequate calcium/vitamin D, and regular monitoring, most people gain far more benefit than risk from osteoporosis treatment.